Skip Navigation

Staff Detail

Skip sharing on social media links


Weinberg, David

Formal Title:

Project Lead for the Human Placenta Project


David Weinberg is acting as project lead for NICHD's Human Placenta Project. This role includes generation of funding opportunities and management of grants related to assessment of human placental development and function across pregnancy. It also includes outreach to diverse scientific communities to raise awareness for this initiative. In his role in the Contraceptive Research Branch, David assists in activities focused on drug and device development.





6710B ROCKLEDGE DRIVE Room 2315D, MSC 7002
Bethesda ,MD 20817

Topics in my portfolio:


David Weinberg received his Ph.D. from the Johns Hopkins University in 1983 for work on the Adenovirus type 2 early region 4.  Following a postdoctoral fellowship, he  joined the pharmaceutical company Merck &Co. in 1989.  Dr. Weinberg spent the next 2 decades in early stage drug discovery focused on a broad array of targets aimed at the treatment of obesity while gaining experience across all aspects of translational research and preclinical drug development.  In 2009, he joined the National Institutes of Health (NIH) as a Health Science Administrator where he managed the review of grant applications across a broad spectrum of scientific topics with particular emphasis in the area of female reproductive research.  In 2014, Dr. Weinberg became the Project Lead for NICHD’s newly launched Human Placenta Project.  The goal of this project is to accelerate the progress towards safe, non-invasive, real-time assessment of placental structure and function across pregnancy. In 2017, Dr. Weinberg joined the Contraceptive Research Branch where he applies his drug discovery and translational research experience to help promote the branch efforts to facilitate discovery and development of new and improved contraceptive drugs and devices.


Featured Items:

The Human Placenta Project:

Publications (PubMed):

The role of melanocortins in body weight regulation: opportunities for the treatment of obesity.
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.
Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity.
BOND National Institues of Health Home Home Division of Intramural Population Health Research